Hypertension and Circulating Cytokines and Angiogenic Factors in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma Treated With Sunitinib: Results From a Phase II Trial

Oncologist- United States

doi 10.1634/theoncologist.2015-0143

Full Text

Abstract

Available in

Date

Authors

Publisher

Alphamed Press

Related search

A Phase 2 Trial of Sunitinib in Patients With Advanced Non–clear Cell Renal Cell Carcinoma

European Urology
Urology
2012English

Safety and Efficacy of Sunitinib for Advanced Non-Clear Cell Renal Cell Carcinoma

Asia-Pacific Journal of Clinical Oncology
MedicineOncology
2015English

Sunitinib Causes Macrocytosis in Patients With Advanced Renal Cell Carcinoma

Current Oncology
Oncology
2010English

A Phase II Trial of Sunitinib in Patients With Renal Cell Cancer and Untreated Brain Metastases

Clinical Genitourinary Cancer
OncologyUrology
2014English

Perioperative Immunomodulation With Interleukin-2 in Patients With Renal Cell Carcinoma: Results of a Controlled Phase II Trial

British Journal of Cancer
Cancer ResearchOncology
2006English

Correlation of C-Met Expression and Outcome in Patients With Renal Cell Carcinoma Treated With Sunitinib

Clinical Genitourinary Cancer
OncologyUrology
2017English

Phase I Trial of Sunitinib and Temsirolimus in Metastatic Renal Cell Carcinoma

Clinical Genitourinary Cancer
OncologyUrology
2015English

Phase III Trial of Adjuvant Sunitinib in Patients With High-Risk Renal Cell Carcinoma: Exploratory Pharmacogenomic Analysis

Clinical Cancer Research
Cancer ResearchOncology
2018English

A Phase I, Open-Label Study of Trebananib Combined With Sorafenib or Sunitinib in Patients With Advanced Renal Cell Carcinoma

Clinical Genitourinary Cancer
OncologyUrology
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2026 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy